IRON
Disc Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$78.93
+38.86%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$72.70
From 52W high−16.13%
Volume8.46M
Market cap$3.03B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$72.70
From 52W high
−16.13%
Volume
8.46M
Market cap
$3.03B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.8x
P/E (TTM)
—
RSI (14)
70.4
MomentumView details →
1D Return
+38.86%
YTD Return
+0.62%
SummaryUpdated Jun 1, 2026
Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biotechnology company founded and based in Watertown, Massachusetts. The company went public in August 2020 and focuses on developing novel treatments for patients suffering from serious blood disorders, specifically hematologic diseases. Disc Medicine builds its therapeutic pipeline by targeting fundamental biological pathways related to red blood cell biology, with particular emphasis on heme biosynthesis and iron homeostasis - the processes by which the body produces red blood cells and manages iron levels.
Similar companies
Latest newsMore news →
Disc Medicine, Inc. announced the commencement of an underwritten public offering of $350 million of common stock and, for certain investors, pre-funded warrants to purchase common stock.4h agoDisc Medicine, Inc. shares rose 34.92% to $76.69 during U.S. trading.10h agoDisc Medicine, Inc. announced that its phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints in adults and adolescents with erythropoietic protoporphyria.10h ago